Nagalo, PSV and a Stranded Asset: Seven Million Euros for Twelve Appearances

All through the summer of 2026, the planning office at PSV Eindhoven prepared two scenarios for Adamo Nagalo: a permanent sale or a loan. Both stopped in the same room — the medical suite at FK Çorum.

The deal collapsed at the examination stage. De Telegraaf published the news in its Friday edition, through long-time PSV watcher Jeroen Kapteijns. The wording was clipped to the point of being dry: Nagalo will not play again for PSV this season. Asked what exactly is wrong, the club declined to answer and cited medical data privacy rules.

A 22-year-old centre-back, a Burkina Faso international, once signed for seven million euros, now has no route onto the pitch and no route out of the club. The real story here is not on the grass. It is in the accounts.

Context: the arc of a contract

Nagalo arrived at PSV from FC Nordsjælland. That is the familiar Dutch model: buy young players from Nordic leagues at moderate cost, develop them inside the Eredivisie, then sell them on to Europe's top five leagues. PSV are neither the first nor the last club to walk that path, and most deals under that model turn a profit.

This one did not.

Across two seasons in Eindhoven, Nagalo made twelve appearances in total. Twelve in two seasons tells you his place in the coaching plan: a rotation option, not a pillar. Before that he had a long layoff with a shoulder injury. Last season he was pushed out to Konyaspor on loan to accumulate playing time.

The club tried to sell. FK Çorum in Turkey was the calculated destination, and the deal advanced far enough for the player to undergo a medical. That is when it collapsed.

One point about sourcing needs to be clear. De Telegraaf has a close PSV beat, and the fact that the paper named its dedicated club writer gives the claim that Nagalo will not play again this season a solid footing. But the transfer fee, the appearance count and the medical details circulating on aggregator sites carry no independent verification. The club is silent. That means the financial half of this story still needs checking, even if the factual half is reasonably firm.

Core: dissecting an investment

Based on my experience watching Eredivisie matches, seven million euros is not a small outlay for a young centre-back. It sits in the band where a club has to think carefully: large enough to enter a multi-year financial plan, small enough not to be an existential gamble. That middle band is exactly where stranded assets breed, because nobody tracks them closely enough.

Do the simple arithmetic. Assume a five-year contract — the common European length — and PSV amortise roughly 1.4 million euros of transfer value per year. After two years, the remaining book value sits near 4.2 million euros. Divided by twelve appearances, each match Nagalo played in a PSV shirt consumed close to 600,000 euros of amortised value.

The core point sits here: PSV paid seven million euros for an asset the market no longer wants to price, and the failed medical at Çorum is the moment that price became public.

In European football, the medical is the buyer's right. Find something outside the acceptable threshold and the buyer cancels, and they do so more and more often. The mechanism protects buyers but concentrates risk on sellers. When a deal dies at the examination stage, the information does not vanish — it enters the market file. Every subsequently interested club knows a buyer walked away on health grounds.

Nagalo's market value is therefore discounted immediately. No statement required. Just one deal dying in a clinic.

PSV's exit routes have narrowed. A clean sale at a good price is barely viable. A loan is the more realistic path, but a loan also requires the receiving club to accept medical risk, and that usually drags PSV into sharing part of the wage. The wage burden does not disappear when a player leaves on loan.

The club also faces an accounting question. When a player's recoverable value falls below his carrying value on the books, the business writes the asset down. In football that is a single line in the annual report that few supporters notice, yet it feeds directly into next season's budget.

One further detail about the direction of travel is telling. PSV bought Nagalo from a Danish development club, then tried to sell into Turkey. That is a reverse flow: from the Nordic development market, through the Dutch league, down into a secondary market. For a 22-year-old once highly rated, it signals that no club in Europe's top leagues was willing to open talks.

Contrarian view: the misunderstanding from outside

The predictable media framing is that PSV have lost a centre-back for the rest of the season. That reading is wrong because it assumes Nagalo was part of the first team. Twelve appearances in two seasons, an average of six a year, is not the portrait of a regularly rotated player. He is a depth option at the end of the bench.

For a club competing on multiple fronts, losing a backup centre-back thins the squad. It does not collapse the defensive system. The fitness knock-on effect on the first-choice pair is indirect, and only becomes visible if PSV suffer an injury in that position during the run-in.

The second misunderstanding concerns blame. It is easy to look at the clinic in Çorum and treat that as the breaking point. The real breaking point sits far earlier — in the medical assessment process before the contract was signed. If a player already has a serious shoulder history and plays an average of six matches a season, the seven-million-euro fee should have been repriced, or attached to buyer-protection clauses.

A dressing room never keeps a secret — only people who do not know how to listen think it stays quiet. At Eindhoven, the fact that a player is not in the coaching plan was never a secret to those inside the room. Only when the deal collapsed did it become news.

The third misunderstanding concerns the line that there is still a chance he could leave PSV. Read it in the right role: that is a seller-side statement in a deal that needs to keep an exit alive. It should not be treated as a forecast. A deal that has already died in a clinic has a far narrower path back to the negotiating table than the phrasing suggests.

People trust the screen; I trust the guy at the end of the bench taking notes by hand. Players on the fringe usually know their position better than any report. And on the fringe, time does not pass by matches — it passes by transfer windows.

Risk and signals to track

Three principal risks in this file, ranked.

Financial risk sits in the highest band. An asset worth seven million euros is close to unsellable while the wage still has to be paid. The most likely path is a loan or a nominal-fee sale, recovering a fraction of the original cost.

The second risk is value destruction through disclosure. News of the failed medical is already in the market. Any future buyer will enter talks assuming a medical problem exists, and will demand compensation in the price.

The third risk belongs to the player himself: a cumulative injury record. The shoulder, then the current undisclosed issue. For a 22-year-old centre-back this is the most important stretch of his career, and every lost season is one that cannot be recovered. For the Burkina Faso national team, losing club minutes also dulls his sharpness ahead of international windows.

On the club side, the thing worth watching is not where Nagalo goes in the next window. It is the impairment line in PSV's annual accounts. If it appears, the story has been confirmed by the books. If it does not, the club is still waiting for a kinder market.

The second signal is whether PSV change their medical process in subsequent deals. A club that treats the medical as a formality will keep buying assets that already carry problems. A club that treats it as a filter will pay less for the same player, or nothing at all.

For Vietnamese football supporters, this is not a distant story. Domestic clubs often sign players on the basis of video reels and agent recommendations, with the medical squeezed in to close the paperwork on time. The cost of that approach does not show up in season one. It shows up in season two, when the player cannot be sold and the wages keep leaving the account on schedule.

Closing

Narrowly, this is news about a centre-back who is not playing. More broadly, it is a record of how a seven-million-euro investment locked up in a single morning in a clinic. European football runs on faith in data, but the medical examination is where data turns into real power.

People call me a source; I call myself someone who can hear the rhythm of the dressing room. And the rhythm at Eindhoven right now is not in the remaining matches of the season. It is in the financial report due in a few months, when one small line confirms what nobody at the Philips Stadion wants to say out loud.

Breaking news does not fall from the sky, you have to make it — but losses always find you, on schedule, with nobody needing to announce them.